nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftaroline fosamil—Neutropenia—Irinotecan—pancreatic cancer	0.00615	0.00615	CcSEcCtD
Ceftaroline fosamil—Phlebitis—Docetaxel—pancreatic cancer	0.00611	0.00611	CcSEcCtD
Ceftaroline fosamil—Anaemia—Tamoxifen—pancreatic cancer	0.006	0.006	CcSEcCtD
Ceftaroline fosamil—Neutropenia—Gemcitabine—pancreatic cancer	0.00599	0.00599	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Sunitinib—pancreatic cancer	0.0058	0.0058	CcSEcCtD
Ceftaroline fosamil—Hyperglycaemia—Gemcitabine—pancreatic cancer	0.00578	0.00578	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Sunitinib—pancreatic cancer	0.00577	0.00577	CcSEcCtD
Ceftaroline fosamil—Renal failure—Irinotecan—pancreatic cancer	0.00577	0.00577	CcSEcCtD
Ceftaroline fosamil—Infestation NOS—Fluorouracil—pancreatic cancer	0.00562	0.00562	CcSEcCtD
Ceftaroline fosamil—Infestation—Fluorouracil—pancreatic cancer	0.00562	0.00562	CcSEcCtD
Ceftaroline fosamil—Renal failure—Gemcitabine—pancreatic cancer	0.00562	0.00562	CcSEcCtD
Ceftaroline fosamil—Erythema—Sunitinib—pancreatic cancer	0.00556	0.00556	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Sunitinib—pancreatic cancer	0.00556	0.00556	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—pancreatic cancer	0.00543	0.00543	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Gemcitabine—pancreatic cancer	0.0054	0.0054	CcSEcCtD
Ceftaroline fosamil—Bradycardia—Irinotecan—pancreatic cancer	0.00536	0.00536	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Tamoxifen—pancreatic cancer	0.00519	0.00519	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Erlotinib—pancreatic cancer	0.00514	0.00514	CcSEcCtD
Ceftaroline fosamil—Anaemia—Sunitinib—pancreatic cancer	0.00514	0.00514	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Erlotinib—pancreatic cancer	0.00514	0.00514	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Erlotinib—pancreatic cancer	0.0051	0.0051	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Gemcitabine—pancreatic cancer	0.00507	0.00507	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Gemcitabine—pancreatic cancer	0.00503	0.00503	CcSEcCtD
Ceftaroline fosamil—Convulsion—Sunitinib—pancreatic cancer	0.00482	0.00482	CcSEcCtD
Ceftaroline fosamil—Hyperkalaemia—Epirubicin—pancreatic cancer	0.0048	0.0048	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Irinotecan—pancreatic cancer	0.00478	0.00478	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Irinotecan—pancreatic cancer	0.00476	0.00476	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—pancreatic cancer	0.0047	0.0047	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Gemcitabine—pancreatic cancer	0.00465	0.00465	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Gemcitabine—pancreatic cancer	0.00463	0.00463	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.00458	0.00458	CcSEcCtD
Ceftaroline fosamil—Constipation—Tamoxifen—pancreatic cancer	0.00453	0.00453	CcSEcCtD
Ceftaroline fosamil—Pain—Tamoxifen—pancreatic cancer	0.00453	0.00453	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.00453	0.00453	CcSEcCtD
Ceftaroline fosamil—Constipation—Erlotinib—pancreatic cancer	0.00449	0.00449	CcSEcCtD
Ceftaroline fosamil—Pain—Erlotinib—pancreatic cancer	0.00449	0.00449	CcSEcCtD
Ceftaroline fosamil—Erythema—Gemcitabine—pancreatic cancer	0.00446	0.00446	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Sunitinib—pancreatic cancer	0.00445	0.00445	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Sunitinib—pancreatic cancer	0.00445	0.00445	CcSEcCtD
Ceftaroline fosamil—Hyperkalaemia—Doxorubicin—pancreatic cancer	0.00444	0.00444	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Sunitinib—pancreatic cancer	0.00441	0.00441	CcSEcCtD
Ceftaroline fosamil—Erythema—Fluorouracil—pancreatic cancer	0.00439	0.00439	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.00434	0.00434	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.00429	0.00429	CcSEcCtD
Ceftaroline fosamil—Neutropenia—Docetaxel—pancreatic cancer	0.00425	0.00425	CcSEcCtD
Ceftaroline fosamil—Anaemia—Irinotecan—pancreatic cancer	0.00424	0.00424	CcSEcCtD
Ceftaroline fosamil—Urticaria—Tamoxifen—pancreatic cancer	0.00421	0.00421	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Tamoxifen—pancreatic cancer	0.00419	0.00419	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Erlotinib—pancreatic cancer	0.00415	0.00415	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Erlotinib—pancreatic cancer	0.00415	0.00415	CcSEcCtD
Ceftaroline fosamil—Anaemia—Gemcitabine—pancreatic cancer	0.00413	0.00413	CcSEcCtD
Ceftaroline fosamil—Phlebitis—Epirubicin—pancreatic cancer	0.00412	0.00412	CcSEcCtD
Ceftaroline fosamil—Anaemia—Fluorouracil—pancreatic cancer	0.00406	0.00406	CcSEcCtD
Ceftaroline fosamil—Infestation NOS—Docetaxel—pancreatic cancer	0.00405	0.00405	CcSEcCtD
Ceftaroline fosamil—Infestation—Docetaxel—pancreatic cancer	0.00405	0.00405	CcSEcCtD
Ceftaroline fosamil—Renal failure—Docetaxel—pancreatic cancer	0.00399	0.00399	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.00392	0.00392	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Tamoxifen—pancreatic cancer	0.00391	0.00391	CcSEcCtD
Ceftaroline fosamil—Pain—Sunitinib—pancreatic cancer	0.00388	0.00388	CcSEcCtD
Ceftaroline fosamil—Constipation—Sunitinib—pancreatic cancer	0.00388	0.00388	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Docetaxel—pancreatic cancer	0.00383	0.00383	CcSEcCtD
Ceftaroline fosamil—Phlebitis—Doxorubicin—pancreatic cancer	0.00381	0.00381	CcSEcCtD
Ceftaroline fosamil—Convulsion—Fluorouracil—pancreatic cancer	0.0038	0.0038	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.00378	0.00378	CcSEcCtD
Ceftaroline fosamil—Pruritus—Tamoxifen—pancreatic cancer	0.00375	0.00375	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Irinotecan—pancreatic cancer	0.00374	0.00374	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.00371	0.00371	CcSEcCtD
Ceftaroline fosamil—Pruritus—Erlotinib—pancreatic cancer	0.00371	0.00371	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Irinotecan—pancreatic cancer	0.00367	0.00367	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Irinotecan—pancreatic cancer	0.00366	0.00366	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.00364	0.00364	CcSEcCtD
Ceftaroline fosamil—Hepatitis—Docetaxel—pancreatic cancer	0.00364	0.00364	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Tamoxifen—pancreatic cancer	0.00363	0.00363	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Docetaxel—pancreatic cancer	0.00359	0.00359	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Sunitinib—pancreatic cancer	0.00359	0.00359	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Sunitinib—pancreatic cancer	0.00359	0.00359	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Erlotinib—pancreatic cancer	0.00359	0.00359	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.00358	0.00358	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Gemcitabine—pancreatic cancer	0.00357	0.00357	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Docetaxel—pancreatic cancer	0.00357	0.00357	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Gemcitabine—pancreatic cancer	0.00357	0.00357	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Gemcitabine—pancreatic cancer	0.00354	0.00354	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Fluorouracil—pancreatic cancer	0.00351	0.00351	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.00351	0.00351	CcSEcCtD
Ceftaroline fosamil—Dizziness—Tamoxifen—pancreatic cancer	0.00351	0.00351	CcSEcCtD
Ceftaroline fosamil—Dizziness—Erlotinib—pancreatic cancer	0.00347	0.00347	CcSEcCtD
Ceftaroline fosamil—Vomiting—Tamoxifen—pancreatic cancer	0.00337	0.00337	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Sunitinib—pancreatic cancer	0.00335	0.00335	CcSEcCtD
Ceftaroline fosamil—Rash—Tamoxifen—pancreatic cancer	0.00334	0.00334	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Tamoxifen—pancreatic cancer	0.00334	0.00334	CcSEcCtD
Ceftaroline fosamil—Vomiting—Erlotinib—pancreatic cancer	0.00334	0.00334	CcSEcCtD
Ceftaroline fosamil—Headache—Tamoxifen—pancreatic cancer	0.00332	0.00332	CcSEcCtD
Ceftaroline fosamil—Rash—Erlotinib—pancreatic cancer	0.00331	0.00331	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Erlotinib—pancreatic cancer	0.0033	0.0033	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Docetaxel—pancreatic cancer	0.0033	0.0033	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Docetaxel—pancreatic cancer	0.00329	0.00329	CcSEcCtD
Ceftaroline fosamil—Headache—Erlotinib—pancreatic cancer	0.00329	0.00329	CcSEcCtD
Ceftaroline fosamil—Hypokalaemia—Epirubicin—pancreatic cancer	0.00323	0.00323	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.00323	0.00323	CcSEcCtD
Ceftaroline fosamil—Pruritus—Sunitinib—pancreatic cancer	0.00321	0.00321	CcSEcCtD
Ceftaroline fosamil—Pain—Irinotecan—pancreatic cancer	0.0032	0.0032	CcSEcCtD
Ceftaroline fosamil—Constipation—Irinotecan—pancreatic cancer	0.0032	0.0032	CcSEcCtD
Ceftaroline fosamil—Erythema—Docetaxel—pancreatic cancer	0.00317	0.00317	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Docetaxel—pancreatic cancer	0.00317	0.00317	CcSEcCtD
Ceftaroline fosamil—Nausea—Tamoxifen—pancreatic cancer	0.00315	0.00315	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.00315	0.00315	CcSEcCtD
Ceftaroline fosamil—Constipation—Gemcitabine—pancreatic cancer	0.00312	0.00312	CcSEcCtD
Ceftaroline fosamil—Pain—Gemcitabine—pancreatic cancer	0.00312	0.00312	CcSEcCtD
Ceftaroline fosamil—Nausea—Erlotinib—pancreatic cancer	0.00312	0.00312	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Sunitinib—pancreatic cancer	0.00311	0.00311	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.00309	0.00309	CcSEcCtD
Ceftaroline fosamil—Pain—Fluorouracil—pancreatic cancer	0.00306	0.00306	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.00306	0.00306	CcSEcCtD
Ceftaroline fosamil—Eosinophilia—Epirubicin—pancreatic cancer	0.00304	0.00304	CcSEcCtD
Ceftaroline fosamil—Dizziness—Sunitinib—pancreatic cancer	0.003	0.003	CcSEcCtD
Ceftaroline fosamil—Hypokalaemia—Doxorubicin—pancreatic cancer	0.00299	0.00299	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Irinotecan—pancreatic cancer	0.00296	0.00296	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Irinotecan—pancreatic cancer	0.00296	0.00296	CcSEcCtD
Ceftaroline fosamil—Anaemia—Docetaxel—pancreatic cancer	0.00293	0.00293	CcSEcCtD
Ceftaroline fosamil—Vomiting—Sunitinib—pancreatic cancer	0.00289	0.00289	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Gemcitabine—pancreatic cancer	0.00288	0.00288	CcSEcCtD
Ceftaroline fosamil—Neutropenia—Epirubicin—pancreatic cancer	0.00287	0.00287	CcSEcCtD
Ceftaroline fosamil—Rash—Sunitinib—pancreatic cancer	0.00286	0.00286	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Sunitinib—pancreatic cancer	0.00286	0.00286	CcSEcCtD
Ceftaroline fosamil—Urticaria—Fluorouracil—pancreatic cancer	0.00285	0.00285	CcSEcCtD
Ceftaroline fosamil—Headache—Sunitinib—pancreatic cancer	0.00285	0.00285	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Fluorouracil—pancreatic cancer	0.00283	0.00283	CcSEcCtD
Ceftaroline fosamil—Eosinophilia—Doxorubicin—pancreatic cancer	0.00281	0.00281	CcSEcCtD
Ceftaroline fosamil—Palpitations—Docetaxel—pancreatic cancer	0.0028	0.0028	CcSEcCtD
Ceftaroline fosamil—Hyperglycaemia—Epirubicin—pancreatic cancer	0.00277	0.00277	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Irinotecan—pancreatic cancer	0.00276	0.00276	CcSEcCtD
Ceftaroline fosamil—Convulsion—Docetaxel—pancreatic cancer	0.00275	0.00275	CcSEcCtD
Ceftaroline fosamil—Infestation NOS—Epirubicin—pancreatic cancer	0.00273	0.00273	CcSEcCtD
Ceftaroline fosamil—Infestation—Epirubicin—pancreatic cancer	0.00273	0.00273	CcSEcCtD
Ceftaroline fosamil—Nausea—Sunitinib—pancreatic cancer	0.0027	0.0027	CcSEcCtD
Ceftaroline fosamil—Renal failure—Epirubicin—pancreatic cancer	0.00269	0.00269	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.00268	0.00268	CcSEcCtD
Ceftaroline fosamil—Neutropenia—Doxorubicin—pancreatic cancer	0.00265	0.00265	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00264	0.00264	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.00259	0.00259	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Docetaxel—pancreatic cancer	0.00259	0.00259	CcSEcCtD
Ceftaroline fosamil—Pruritus—Gemcitabine—pancreatic cancer	0.00258	0.00258	CcSEcCtD
Ceftaroline fosamil—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.00256	0.00256	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Irinotecan—pancreatic cancer	0.00256	0.00256	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Docetaxel—pancreatic cancer	0.00254	0.00254	CcSEcCtD
Ceftaroline fosamil—Pruritus—Fluorouracil—pancreatic cancer	0.00253	0.00253	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Docetaxel—pancreatic cancer	0.00253	0.00253	CcSEcCtD
Ceftaroline fosamil—Infestation NOS—Doxorubicin—pancreatic cancer	0.00253	0.00253	CcSEcCtD
Ceftaroline fosamil—Infestation—Doxorubicin—pancreatic cancer	0.00253	0.00253	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Docetaxel—pancreatic cancer	0.00251	0.00251	CcSEcCtD
Ceftaroline fosamil—Bradycardia—Epirubicin—pancreatic cancer	0.0025	0.0025	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Gemcitabine—pancreatic cancer	0.00249	0.00249	CcSEcCtD
Ceftaroline fosamil—Renal failure—Doxorubicin—pancreatic cancer	0.00249	0.00249	CcSEcCtD
Ceftaroline fosamil—Dizziness—Irinotecan—pancreatic cancer	0.00247	0.00247	CcSEcCtD
Ceftaroline fosamil—Hepatitis—Epirubicin—pancreatic cancer	0.00246	0.00246	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Fluorouracil—pancreatic cancer	0.00245	0.00245	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Epirubicin—pancreatic cancer	0.00242	0.00242	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Epirubicin—pancreatic cancer	0.00241	0.00241	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.00239	0.00239	CcSEcCtD
Ceftaroline fosamil—Vomiting—Irinotecan—pancreatic cancer	0.00238	0.00238	CcSEcCtD
Ceftaroline fosamil—Dizziness—Fluorouracil—pancreatic cancer	0.00237	0.00237	CcSEcCtD
Ceftaroline fosamil—Rash—Irinotecan—pancreatic cancer	0.00236	0.00236	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Irinotecan—pancreatic cancer	0.00236	0.00236	CcSEcCtD
Ceftaroline fosamil—Headache—Irinotecan—pancreatic cancer	0.00234	0.00234	CcSEcCtD
Ceftaroline fosamil—Vomiting—Gemcitabine—pancreatic cancer	0.00232	0.00232	CcSEcCtD
Ceftaroline fosamil—Bradycardia—Doxorubicin—pancreatic cancer	0.00231	0.00231	CcSEcCtD
Ceftaroline fosamil—Rash—Gemcitabine—pancreatic cancer	0.0023	0.0023	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Gemcitabine—pancreatic cancer	0.0023	0.0023	CcSEcCtD
Ceftaroline fosamil—Headache—Gemcitabine—pancreatic cancer	0.00228	0.00228	CcSEcCtD
Ceftaroline fosamil—Vomiting—Fluorouracil—pancreatic cancer	0.00228	0.00228	CcSEcCtD
Ceftaroline fosamil—Hepatitis—Doxorubicin—pancreatic cancer	0.00227	0.00227	CcSEcCtD
Ceftaroline fosamil—Rash—Fluorouracil—pancreatic cancer	0.00226	0.00226	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Fluorouracil—pancreatic cancer	0.00226	0.00226	CcSEcCtD
Ceftaroline fosamil—Headache—Fluorouracil—pancreatic cancer	0.00224	0.00224	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.00224	0.00224	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.00223	0.00223	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Epirubicin—pancreatic cancer	0.00223	0.00223	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Doxorubicin—pancreatic cancer	0.00223	0.00223	CcSEcCtD
Ceftaroline fosamil—Nausea—Irinotecan—pancreatic cancer	0.00222	0.00222	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Epirubicin—pancreatic cancer	0.00222	0.00222	CcSEcCtD
Ceftaroline fosamil—Constipation—Docetaxel—pancreatic cancer	0.00221	0.00221	CcSEcCtD
Ceftaroline fosamil—Pain—Docetaxel—pancreatic cancer	0.00221	0.00221	CcSEcCtD
Ceftaroline fosamil—Nausea—Gemcitabine—pancreatic cancer	0.00216	0.00216	CcSEcCtD
Ceftaroline fosamil—Erythema—Epirubicin—pancreatic cancer	0.00214	0.00214	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Epirubicin—pancreatic cancer	0.00214	0.00214	CcSEcCtD
Ceftaroline fosamil—Nausea—Fluorouracil—pancreatic cancer	0.00213	0.00213	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.00211	0.00211	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Doxorubicin—pancreatic cancer	0.00206	0.00206	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Doxorubicin—pancreatic cancer	0.00205	0.00205	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Docetaxel—pancreatic cancer	0.00204	0.00204	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Docetaxel—pancreatic cancer	0.00204	0.00204	CcSEcCtD
Ceftaroline fosamil—Erythema—Doxorubicin—pancreatic cancer	0.00198	0.00198	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Doxorubicin—pancreatic cancer	0.00198	0.00198	CcSEcCtD
Ceftaroline fosamil—Anaemia—Epirubicin—pancreatic cancer	0.00198	0.00198	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Docetaxel—pancreatic cancer	0.00191	0.00191	CcSEcCtD
Ceftaroline fosamil—Palpitations—Epirubicin—pancreatic cancer	0.00189	0.00189	CcSEcCtD
Ceftaroline fosamil—Convulsion—Epirubicin—pancreatic cancer	0.00185	0.00185	CcSEcCtD
Ceftaroline fosamil—Pruritus—Docetaxel—pancreatic cancer	0.00183	0.00183	CcSEcCtD
Ceftaroline fosamil—Anaemia—Doxorubicin—pancreatic cancer	0.00183	0.00183	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.00181	0.00181	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Docetaxel—pancreatic cancer	0.00177	0.00177	CcSEcCtD
Ceftaroline fosamil—Palpitations—Doxorubicin—pancreatic cancer	0.00175	0.00175	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Epirubicin—pancreatic cancer	0.00174	0.00174	CcSEcCtD
Ceftaroline fosamil—Convulsion—Doxorubicin—pancreatic cancer	0.00171	0.00171	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Epirubicin—pancreatic cancer	0.00171	0.00171	CcSEcCtD
Ceftaroline fosamil—Dizziness—Docetaxel—pancreatic cancer	0.00171	0.00171	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Epirubicin—pancreatic cancer	0.00171	0.00171	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Epirubicin—pancreatic cancer	0.00169	0.00169	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.00167	0.00167	CcSEcCtD
Ceftaroline fosamil—Vomiting—Docetaxel—pancreatic cancer	0.00164	0.00164	CcSEcCtD
Ceftaroline fosamil—Rash—Docetaxel—pancreatic cancer	0.00163	0.00163	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Docetaxel—pancreatic cancer	0.00163	0.00163	CcSEcCtD
Ceftaroline fosamil—Headache—Docetaxel—pancreatic cancer	0.00162	0.00162	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.00161	0.00161	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Doxorubicin—pancreatic cancer	0.00158	0.00158	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.00158	0.00158	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Doxorubicin—pancreatic cancer	0.00157	0.00157	CcSEcCtD
Ceftaroline fosamil—Nausea—Docetaxel—pancreatic cancer	0.00154	0.00154	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.00151	0.00151	CcSEcCtD
Ceftaroline fosamil—Pain—Epirubicin—pancreatic cancer	0.00149	0.00149	CcSEcCtD
Ceftaroline fosamil—Constipation—Epirubicin—pancreatic cancer	0.00149	0.00149	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.00143	0.00143	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.00139	0.00139	CcSEcCtD
Ceftaroline fosamil—Urticaria—Epirubicin—pancreatic cancer	0.00139	0.00139	CcSEcCtD
Ceftaroline fosamil—Constipation—Doxorubicin—pancreatic cancer	0.00138	0.00138	CcSEcCtD
Ceftaroline fosamil—Pain—Doxorubicin—pancreatic cancer	0.00138	0.00138	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Epirubicin—pancreatic cancer	0.00138	0.00138	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Epirubicin—pancreatic cancer	0.00138	0.00138	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.00132	0.00132	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Epirubicin—pancreatic cancer	0.00129	0.00129	CcSEcCtD
Ceftaroline fosamil—Urticaria—Doxorubicin—pancreatic cancer	0.00128	0.00128	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Doxorubicin—pancreatic cancer	0.00128	0.00128	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Doxorubicin—pancreatic cancer	0.00128	0.00128	CcSEcCtD
Ceftaroline fosamil—Pruritus—Epirubicin—pancreatic cancer	0.00123	0.00123	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Epirubicin—pancreatic cancer	0.00119	0.00119	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Doxorubicin—pancreatic cancer	0.00119	0.00119	CcSEcCtD
Ceftaroline fosamil—Dizziness—Epirubicin—pancreatic cancer	0.00115	0.00115	CcSEcCtD
Ceftaroline fosamil—Pruritus—Doxorubicin—pancreatic cancer	0.00114	0.00114	CcSEcCtD
Ceftaroline fosamil—Vomiting—Epirubicin—pancreatic cancer	0.00111	0.00111	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Doxorubicin—pancreatic cancer	0.0011	0.0011	CcSEcCtD
Ceftaroline fosamil—Rash—Epirubicin—pancreatic cancer	0.0011	0.0011	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Epirubicin—pancreatic cancer	0.0011	0.0011	CcSEcCtD
Ceftaroline fosamil—Headache—Epirubicin—pancreatic cancer	0.00109	0.00109	CcSEcCtD
Ceftaroline fosamil—Dizziness—Doxorubicin—pancreatic cancer	0.00107	0.00107	CcSEcCtD
Ceftaroline fosamil—Nausea—Epirubicin—pancreatic cancer	0.00104	0.00104	CcSEcCtD
Ceftaroline fosamil—Vomiting—Doxorubicin—pancreatic cancer	0.00103	0.00103	CcSEcCtD
Ceftaroline fosamil—Rash—Doxorubicin—pancreatic cancer	0.00102	0.00102	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Doxorubicin—pancreatic cancer	0.00102	0.00102	CcSEcCtD
Ceftaroline fosamil—Headache—Doxorubicin—pancreatic cancer	0.00101	0.00101	CcSEcCtD
Ceftaroline fosamil—Nausea—Doxorubicin—pancreatic cancer	0.000959	0.000959	CcSEcCtD
